UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the |
| Date of Report: January 28, 2010 (Date of earliest event reported) | ||||
| Theravance, Inc. (Exact name of registrant as specified in its charter) | ||||
| Delaware (State or other jurisdiction of incorporation) | 000-30319 (Commission File Number) | 94-3265960 (IRS Employer Identification Number) | ||
| 901 Gateway Boulevard, South San Francisco, CA (Address of principal executive offices) | 94080 (Zip Code) | |||
650-808-6000 (Registrant's telephone number, including area code) | ||||
| Not Applicable (Former Name or Former Address, if changed since last report) | ||||
| Item 8.01. Other Events On January 28, 2010, Theravance, Inc. (the "Company") issued a press release announcing that it received from the U.S. Food and Drug Administration (FDA) a letter indicating that Theravance's response to the November 2009 Complete Response letter for the telavancin New Drug Application for the treatment of nosocomial pneumonia is incomplete and that the review clock will not start until the FDA receives a complete response. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference. Members of the Company's management will discuss this announcement on a conference call today, January 28, 2010, at 5:00 p.m. Eastern Standard Time. Item 9.01. Financial Statements and Exhibits (d) Exhibits Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. |
| Dated: January 28, 2010 | THERAVANCE, INC. By: /s/ Michael W. Aguiar |
| Exhibit No. | Description |
| 99.1 | Press Release of Theravance, Inc. dated January 28, 2010 |
